Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20080003570external-prioritypatent/EP2096171A1/en
Application filed by Julius-Maximilians-Universität WürzburgfiledCriticalJulius-Maximilians-Universität Würzburg
Publication of RS52904BpublicationCriticalpatent/RS52904B/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms
(AREA)
Abstract
Jedinjenje, naznačeno time, da sadrži modifikovani oligonukleotid koji obuhvata 12 do 30 spojenih nukleozida, pri čemu modifikovani oligonukleotid ima nukleobaznu sekvencu koja je komplementarna sa miR-21 ili njenim prekursorom, za upotrebu u tretmanu, prevenciji ili dijagnozi fibroze u nekom subjektu.Prijava sadrži još 14 patentnih zahteva.A compound comprising a modified oligonucleotide comprising 12 to 30 fused nucleosides, wherein the modified oligonucleotide has a nucleobase sequence that is complementary to miR-21 or its precursor for use in the treatment, prevention or diagnosis of fibrosis in an entity. another 14 patent claims.
RS20130340A2008-02-272009-02-26Microrna (mirna) mir-21 for diagnostic and therapeutic purposes
RS52904B
(en)
Compounds derived from pyrrolo - (2-3-d] -pyrimidin-7 (6h) -tetrahydrofuran-2-yl phosphonamidate, pharmaceutical composition; and its use in the treatment of viral diseases.
Compounds derived from (piran-) or (thiopiran-) quinazolinadione, phosphodiesterase 7 (pde7) inhibitors; preparation procedure; pharmaceutical composition; and use to treat an inflammatory, immunoinflammatory, cardiovascular, central nervous system and / or peripheral disease.